These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

994 related items for PubMed ID: 21383296

  • 1. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.
    J Clin Oncol; 2011 Apr 10; 29(11):1452-7. PubMed ID: 21383296
    [Abstract] [Full Text] [Related]

  • 2. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
    Shim H, Oh JI, Park SH, Jang S, Park CJ, Huh J, Suh C, Chi HS.
    J Clin Pathol; 2013 May 10; 66(5):420-5. PubMed ID: 23610041
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M.
    Am J Hematol; 2015 Nov 10; 90(11):1041-6. PubMed ID: 26260224
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
    Yang S, Yu Y, Jun-Min L, Jian-Qing M, Qiu-Sheng C, Yu C, Wei-Li Z, Jian-Hua Y, Hui-Jin Z, Yan W, Li W, Shu C, Zhi-Xiang S.
    Ann Hematol; 2009 Sep 10; 88(9):863-9. PubMed ID: 19205655
    [Abstract] [Full Text] [Related]

  • 12. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
    Yi SH, Xu Y, Zou DH, An G, Zhao YZ, Qi JY, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2009 May 10; 30(5):307-12. PubMed ID: 19799125
    [Abstract] [Full Text] [Related]

  • 13. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
    Gaudio F, Giordano A, Perrone T, Pastore D, Curci P, Delia M, Napoli A, de' Risi C, Spina A, Ricco R, Liso V, Specchia G.
    Acta Haematol; 2011 May 10; 126(1):44-51. PubMed ID: 21430371
    [Abstract] [Full Text] [Related]

  • 14. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST.
    Ann Hematol; 2009 May 10; 88(5):417-24. PubMed ID: 18777110
    [Abstract] [Full Text] [Related]

  • 15. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK, Chung JS, Sung-Yong O, Lee GW, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ, Shin DH, Yun EY.
    Ann Hematol; 2010 Oct 10; 89(10):985-91. PubMed ID: 20428871
    [Abstract] [Full Text] [Related]

  • 16. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK, Lymphoma Study Division of the Korean Cancer Study Group.
    Ann Hematol; 2006 Apr 10; 85(4):257-62. PubMed ID: 16416337
    [Abstract] [Full Text] [Related]

  • 17. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN.
    Zhonghua Zhong Liu Za Zhi; 2005 Mar 10; 27(3):174-6. PubMed ID: 15946571
    [Abstract] [Full Text] [Related]

  • 18. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
    Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, Gallo A, Lopez-Ilasaca M, Butera JN, Sotomayor EM.
    Am J Hematol; 2011 Aug 10; 86(8):663-7. PubMed ID: 21761432
    [Abstract] [Full Text] [Related]

  • 19. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S.
    Ann Hematol; 2012 Mar 10; 91(3):383-90. PubMed ID: 21822617
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.
    Int J Oncol; 2011 Dec 10; 39(6):1413-20. PubMed ID: 21874232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.